Cigna Group 8-K Filing
Ticker: CI · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1739940
| Field | Detail |
|---|---|
| Company | Cigna Group (CI) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cigna Group (ticker: CI) to the SEC on Nov 18, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ich registered Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.).
How long is this filing?
Cigna Group's 8-K filing is 2 pages with approximately 740 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2025-11-18 16:15:46
Key Financial Figures
- $0.01 — ich registered Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.
Filing Documents
- ef20059558_8k.htm (8-K) — 28KB
- 0001140361-25-042597.txt ( ) — 152KB
- ci-20251022.xsd (EX-101.SCH) — 4KB
- ci-20251022_lab.xml (EX-101.LAB) — 21KB
- ci-20251022_pre.xml (EX-101.PRE) — 16KB
- ef20059558_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On October 22, 2025, the Board of Directors (the "Board") of The Cigna Group (the "Company") approved changes to the Board's committee structure, effective January 1, 2026 (the "Effective Date"). Recognizing and responding to the dynamic landscape of the health services industry, these changes reflect the Board's ongoing commitment to strong corporate governance practices. The Board undertook a comprehensive review of the overall committee structure and the responsibilities of each committee, including ensuring the committees' scope of responsibilities are aligned with the Company's strategic priorities, remains balanced and appropriate, and provides additional opportunities for the full Board to focus on matters significant to the Company. Changes related to the responsibilities of the Compliance Committee . 1. Compliance Committee . Given that the scope of the Compliance Committee's oversight responsibilities was reduced upon the sale of the Company's Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses in March 2025, the responsibilities of the Compliance Committee will be assumed by the Board and other committees and the Compliance Committee will cease being a separate standing committee. 2. Audit and Compliance Committee . Oversight of compliance matters remains an area of priority for the Board, and the Audit Committee will be renamed as the "Audit and Compliance Committee" with responsibility for enterprise compliance matters. 3. Corporate Governance Committee . The Corporate Governance Committee will assume oversight of the Company's ethics program, including with respect to the Company's Code of Ethics and Principles of Conduct and the Director Code of Business Conduct and Ethics. The Corporate Governance Committee will also oversee public clinical reporting. 4. Oversight of Clinical Compliance. Oversight of clinical compli